Impairment in Glucose Homeostasis Among Obese Adolescents in High Risk Diabetes Prone Population - Jisr Az-Zarqa Village

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2012 by Meir Medical Center
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01535105
First received: February 14, 2012
Last updated: March 13, 2013
Last verified: February 2012
  Purpose

Obesity is increasing all over the world in adults, adolescents and children,and is followed by morbidity, including the metabolic syndrome.

Hypothesis: Among obese adolescents there is a subgroup with impaired glucose homeostasis

The aim of the study is to identify adolescents with impaired glucose metabolism, 12-18 years, among high risk diabetes prone population, for diagnosis and treatment.


Condition
Glucose Metabolism Disorders

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional

Resource links provided by NLM:


Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • Frequency of Impaired Glucose Homeostasis among obese adolescents in high risk diabetes prone population [ Time Frame: one year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Description of the metabolic profile in obese adolescents [ Time Frame: One year ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: August 2012
Estimated Study Completion Date: April 2017
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Obese Adolescents

  Eligibility

Ages Eligible for Study:   12 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects of the study will be selected from a primary care clinic

Criteria

Inclusion Criteria:

  • Clinical diagnosis of obesity

Exclusion Criteria:

  • History of disease or drug therapy affecting glucose metabolism
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01535105

Contacts
Contact: Nehama Zuckerman-Levin, MD 972-524354143 zuckerln@netvision.net.il

Locations
Israel
Clalit Health Services Clinic Recruiting
Jisr az-Zarqa village, Israel
Contact: Nehama Zuckerman-Levin, MD    072524354143    zuckerln@netvision.net.il   
Principal Investigator: Nehama Zuckerman-Levin, MD         
Sponsors and Collaborators
Meir Medical Center
Investigators
Principal Investigator: Nehama Zuckerman-Levin, MD Clalit Health Services
  More Information

No publications provided

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01535105     History of Changes
Other Study ID Numbers: Gl homeostasis and obesity
Study First Received: February 14, 2012
Last Updated: March 13, 2013
Health Authority: Israel: Ethics Commission

Additional relevant MeSH terms:
Metabolic Diseases
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on August 27, 2014